Available Online at www.ijcsmc.com

International Journal of Computer Science and Mobile Computing

A Monthly Journal of Computer Science and Information Technology

ISSN 2320–088X
IMPACT FACTOR: 7.056

IJCSMC, Vol. 14, Issue. 2, February 2025, pg.52 – 60

Enhancing Melanoma Diagnosis through the Integration of Artificial Intelligence: Identifying Gaps and Future Research Directions

Mahesh Naidu K[1]; Padmavathamma M[2]

[1]Research Scholar, Department of Computer Science, Sri Venkateswara University, Tirupati, India
[2]Professor, Department of Computer Science, Sri Venkateswara University, Tirupati, India

DOI: https://doi.org/10.47760/ijcsmc.2025.v14i02.006

Abstract: Melanoma (Skin cancer) remains a significant global health challenge because of its increasing incidence and economic impact. Despite advances in diagnostics and treatment, significant research gaps hinder effective management. This study aims to identify and illuminate these gaps, providing a comprehensive overview of current skin cancer research in technology integration perspective. The focus is on integrating advanced diagnostic technologies, such as electrical impedance spectroscopy and multispectral imaging, into clinical practice to improve early detection. The study also explores the potential of nanotechnology for targeted treatment and addresses challenges like drug resistance and the economic burden of treatment. This research aims to develop effective and personalized skin cancer treatments by incorporating patient perspectives and validating AI technologies. The goal is to advance skin cancer management, improve patient outcomes, and reduce the global burden of the disease.

Keywords: Melanoma, Skin Cancer, Diagnostic Technologies, Artificial Intelligence, Deep Learning, Machine Learning, Nanotechnology, Drug Resistance, Economic Impact

I. INTRODUCTION

Melanoma (Skin cancer) remains a significant global health challenge with its increasing incidence and significant economic impact [1][2]. Despite significant advances in diagnostics and treatment, major research gaps hinder effective treatment and management of disease. This comprehensive study aims to identify and illuminate these gaps, providing a comprehensive overview of current skin cancer research and highlighting areas requiring further exploration [3][4][5][6]. The focus is on integrating advanced diagnostic technologies into standard clinical practice. Innovations such as electrical impedance spectroscopy and multispectral imaging have shown the potential to improve the accuracy of skin cancer detection [7][8]. These non-invasive, aim, and quantitative tools can significantly improve the early detection of skin cancer [9]. However, clinical adoption of

© 2025, IJCSMC All Rights Reserved, ZAIN Publications, Fridhemsgatan 62, 112 46, Stockholm, Sweden

these diagnostic advances is often hindered by high costs and lack of training. To this end, to close the gap, collaborative initiatives are essential to develop affordable, accessible, and user-friendly diagnostic tools that can be seamlessly integrated into routine clinical practice. Such efforts could include partnerships between research institutions, healthcare providers, and technology companies to ensure sustainable and scalable development and implementation of these technologies. Another critical area requiring attention is early detection of skin cancer, particularly nonmelanoma types[7]. Existing methods are often impractical or inaccessible, causing the development of non-invasive, inexpensive, and widely available early detection techniques. Public awareness and education are crucial in promoting regular skin checks and early medical consultations.[10].

Nanotechnology offers promising opportunities for treating skin cancer by enabling the targeted delivery of therapeutic agents and reducing side effects. However, challenges such as ensuring targeted delivery, long-term safety, and regulatory barriers must be overcome to translate these advances into clinical practice. Drug resistance poses significant challenges in the treatment of skin cancer, especially in advanced stages. The economic burden of treating skin cancer highlights the need for cost-effective strategies and health economic studies to evaluate new treatments and technologies [11]. Incorporating patient perspectives, validating machine learning and AI technologies, and advancing molecular biology research is critical to developing effective and personalized skin cancer treatments. By addressing these gaps, this study aims to advance skin cancer management, ultimately improving outcomes and reducing the global burden of the disease [12][13].

II. OBJECTIVE OF THE STUDY

This study examines advances in skin cancer research, focusing on AI integration for detection, noncarriers, economic impact, epidemiology, molecular biology, and current treatment strategies. It also provides future directions, research gaps and a conceptual framework.

III. METHODOLOGY

This study draws on a comprehensive literature review to identify existing advances and areas requiring further investigation. Peer-reviewed articles, clinical trial reports, and epidemiological data form the backbone of secondary data analysis, ensuring a comprehensive and in-depth understanding of the current state of skin cancer research [14]. The methodology highlights patterns and inconsistencies in current practices by synthesizing insights from diverse sources, including studies of nanotechnology, AI-based diagnostics, and molecular biology. It provides insights into new trends and technological gaps[15]. The study uses experimental research and clinical validation studies to explore the integration of diagnostic technologies, such as electrical impedance spectroscopy (EIS) and multispectral imaging. Studies of successful technology integration in healthcare systems are analyzed to determine best practices and identify barriers to adoption [16][17]. The focus is on the role of cost, training, and clinical applicability of these technologies. The study investigates new non-invasive biomarkers, imaging technologies, and AI algorithms for early detection by evaluating the design and results of ongoing research projects and clinical trials. Public health initiatives and educational campaigns will also be examined to assess their effectiveness in promoting regular skin examinations and consultations. Nontechnological treatments are analyzed through a meta-analysis of preclinical and clinical studies, assessing nanoparticle-based therapies' efficacy, safety, and scalability [18][19]. An important part of the methodology is the study of the economic impact of skin cancer treatment. Based on data from health systems, cost-effectiveness analyses, and health economic models, focus on the financial burden of current treatments and the potential savings from early detection and new therapies. This is supplemented by surveys in which patient perspectives are recorded, and attitudes toward AI, new technologies, and treatment options are examined. Machine learning (ML) and AI research are validated by verifying algorithmic performance against various clinical datasets, with an emphasis on accuracy, ethical considerations, and algorithmic bias[20][21]. Molecular biology relies on laboratory research results and genomic studies to identify potential biomarkers and therapeutic targets. With this multi-pronged approach, the study aims to provide actionable recommendations to address the identified research gaps and advance the diagnosis and treatment of skin cancer [22][23].

IV. LITERATURE REVIEW

The current state of skin cancer research highlights advances in treatment modalities, economic impact, detection methods, and epidemiology. Because of their small size and ability to deliver drugs directly to cancer cells, nanocarriers have shown promise for improving the effectiveness of skin cancer treatments. This approach improves therapeutic outcomes and minimizes the side effects of conventional treatments [24]. The economic burden of skin cancer treatment was significant in the United States from 2012 to 2018, with costs continually increasing. This highlights the need for more cost-effective treatment strategies and early detection methods to reduce the financial burden on healthcare systems and patients. Advances in nanoparticle-based treatment approaches highlight the potential of nanotechnology to revolutionize skin cancer therapy. These nanoparticles

© 2025, IJCSMC All Rights Reserved, ZAIN Publications, Fridhemsgatan 62, 112 46, Stockholm, Sweden

can be engineered to target specific cancer cells, increasing the precision and effectiveness of treatments (Zeng et al., 2023). Significant advances have been made in skin cancer detection methods, particularly by integrating artificial intelligence (AI) and machine learning (ML) technologies. Networks of neural search architectures have been used to detect dental diseases from X-ray images, demonstrating the potential of AI in medical diagnostics [25][26][27]. Similarly, AI and ML have been used in skin cancer detection and classification, with deep learning models outperforming traditional diagnostic methods [28]. These technologies improve the accuracy of diagnoses and enable early detection, which is critical for successful treatment outcomes. The clinical ABCDE rule for early detection of melanoma remains a fundamental tool for physicians and helps identify suspicious lesions [29][30]. Five-year survival rates for patients with nodular and superficially extending melanomas in the United States highlight the importance of early detection and effective treatment strategies in improving patient outcomes.[31] The epidemiology of skin cancer, as observed in the Japanese National Cancer Registry from 2016 to 2017, provides valuable insights into the prevalence and incidence of the disease. Understanding epidemiological trends is critical to developing targeted prevention and treatment strategies. The molecular biology of keratinocyte skin cancers has also been updated, providing new perspectives on the underlying mechanisms of these cancers [32][33]. This knowledge is crucial for developing new therapeutic approaches and improving existing treatments. The role of the tumour microenvironment in skin carcinogenesis has been studied, and the complex interactions between cancer cells and their environment have been highlighted [34][35]. This understanding is critical to developing therapies that target cancer cells and the supportive environment that promotes their growth and spread. Overall, the references provided provide a comprehensive overview of the current state of skin cancer research and highlight the advances and challenges in treatment, detection, and epidemiology. Current studies have continued to push the boundaries of skin cancer research. For example, using artificial intelligence to diagnose skin cancer has shown promising results. A meta-analysis by [36] demonstrated the accuracy of AI in diagnosing nonmelanoma skin cancer. Another focus was the development of machine learning models to detect skin cancer. [37][38] explored the role of machine learning and deep learning approaches in skin cancer detection and highlighted their potential to improve diagnostic accuracy. Integrating AI and machine learning into medical diagnostics revolutionizes the field, offering more accurate and efficient early detection and treatment methods. Advances in treatment strategies have been remarkable [38]. Immunotherapy and targeted therapies have led to significant improvements in patient outcomes. For example, melanoma with BRAF mutations could be successfully treated by combining BRAF and MEK inhibitors [39]. The approval of new therapies, such as B. Lifeline in advanced melanoma, has given new hope to patients with unresectable or metastatic melanoma. These advances highlight the importance of continued research and innovation in skin cancer treatment. Current studies provide a comprehensive overview of the current status of skin cancer research[40]. Advances in treatment modalities, detection methods, and understanding of the epidemiology and molecular biology of the disease are paving the way for more effective and targeted therapies. Integrating AI and machine learning into medical diagnostics revolutionizes the field, offering more accurate and efficient early detection and treatment methods. Continuous research and innovation are essential to improve patient outcomes and reduce the burden of skin cancer on healthcare systems and patients worldwide[22][4].

V. RESEARCH GAP

The following highlights the need for further research and collaboration to address identified skin cancer diagnosis and treatment gaps:

Integration of Diagnostic Technologies

Despite significant advances in skin cancer diagnosis, gaps remain in its practical application in clinical settings. This gap can be attributed to several factors, including the high equipment cost, the lack of training of healthcare professionals, and the need for more robust clinical trials to validate these technologies. There is a need for seamless integration of these diagnostic tools into existing clinical workflows to ensure they are user-friendly and efficient[41][42]. Closing this gap requires collaboration between technology developers, healthcare providers, and policymakers to create affordable, accessible, and effective diagnostic solutions that can be easily implemented.[43].

Early Detection and Treatment

Early detection of skin cancer, particularly nonmelanoma skin cancer, is critical for effective treatment and better patient outcomes. However, early detection methods are not always practical or accessible[44][7]. Further research is needed to develop non-invasive, cost-effective, and widely accessible early detection techniques. This includes research into new biomarkers, imaging technologies, and artificial intelligence (AI) algorithms that can accurately detect early-stage skin cancer. Public awareness campaigns and education programs are essential for promoting regular skin examinations and early consultation with healthcare professionals. By

© 2025, IJCSMC All Rights Reserved, ZAIN Publications, Fridhemsgatan 62, 112 46, Stockholm, Sweden

improving early detection methods and increasing public awareness, we can significantly reduce the morbidity and mortality associated with skin cancer[45].

Nanotechnology in Treatment

Nanotechnology has shown successful potential in treating skin cancer by enabling the targeted delivery of therapeutic agents and minimizing side effects. A significant challenge is to ensure the targeted delivery of nanoparticles to cancer cells while avoiding healthy tissue. Further research into the long-term safety and effectiveness of nontechnological treatments is needed. Regulatory hurdles and the high cost of developing and manufacturing nanomedicine also represent significant obstacles. Addressing these challenges requires interdisciplinary collaboration between researchers, clinicians and regulators.

Drug Resistance

Drug resistance represents a significant challenge in the treatment of skin cancer, particularly at advanced stages. Understanding the mechanisms of drug resistance and developing strategies to overcome them are critical to improving treatment outcomes[22][19]. Research is needed to identify genetic and molecular factors contributing to drug resistance in skin cancer cells. The combination of therapies is required to target multiple cancer progression and resistance pathways. By combating drug resistance, we can improve the effectiveness of treatments and develop new therapeutic strategies that can effectively combat skin cancer[34][22].

Economic Burden

The economic burden of treating skin cancer is significant and involves high costs for diagnosis, treatment, and long-term care. There is a need for research into cost-effective treatment strategies that can reduce the financial burden on patients and healthcare systems[46]. This includes researching the use of generic drugs, developing more affordable diagnostic tools, and implementing preventive measures to reduce the incidence of skin cancer. Health economic studies are needed to assess the cost-effectiveness of new treatments and technologies [47]. By addressing the economic burden of skin cancer, we can ensure that patients have access to affordable and effective care.

Patient Perspectives

Incorporating the patient perspective into developing and implementing new technologies for early skin cancer detection and treatment is critical to improving acceptance and effectiveness. Research is needed to understand patient attitudes toward AI and other advanced technologies in skin cancer treatment[48][49][50]. This includes examining trust, perceived benefits, and potential concerns. Patient-centered approaches should design and implement new technologies to meet patients' needs and preferences[51]. By incorporating the patient's perspective, we can develop more effective and acceptable solutions for treating skin cancer.

Machine Learning and AI

While machine learning and AI have shown promise in detecting and diagnosing skin cancer, further research is needed regarding their accuracy and reliability in real clinical settings[52][53][38]. This includes validating AI algorithms against large, diverse data sets and conducting clinical trials to evaluate their performance in real-world settings. There is a need for research on the ethical and legal implications of using AI in Healthcare, including privacy, algorithmic bias, and accountability[20][21]. Addressing these challenges will ensure that AI technologies for skin cancer are safe, effective, and ethical.

Molecular Biology

Understanding the molecular biology of different skin cancers is crucial for developing targeted and effective treatment. Research is needed to identify genetic and molecular markers that can be used for diagnosis, prognosis, and treatment selection. By expanding our understanding of the molecular biology of skin cancer, we can develop more personalized and effective treatment strategies that improve patient outcomes.

© 2025, IJCSMC All Rights Reserved, ZAIN Publications, Fridhemsgatan 62, 112 46, Stockholm, Sweden

Conceptual Framework for Skin Cancer Diagnosis and Treatment Advancement



1. Integration of Diagnostic Technologies Incorporating advanced diagnostic tools such as Electrical Impedance Spectroscopy (EIS) and multispectral imaging improves early skin cancer detection. By developing affordable, user-friendly diagnostic devices through rigorous clinical trials, healthcare providers can enhance accuracy and efficiency in skin cancer diagnosis. This step ensures precise identification, reducing the likelihood of misdiagnosis and improving patient outcomes.

2. Early Detection and Treatment Early detection reduces skin cancer mortality. Focusing on noninvasive, cost-effective technologies for nonmelanoma skin cancers enhances accessibility to screening. Public awareness campaigns encourage proactive health management. This approach minimizes the disease burden by promoting early diagnosis, reducing complications, and increasing survival rates through timely and targeted interventions.

3. Nanotechnology in Treatment. Nanotechnology offers revolutionary methods for delivering therapeutic agents directly to cancerous cells. By utilizing nanoparticles, treatments become more targeted, minimizing damage to healthy tissues. Long-term safety and effectiveness are achieved through controlled delivery systems. This innovation ensures lower side effects, higher precision, and improved patient comfort during skin cancer therapy.

4. Understanding genetic and molecular contributors to drug resistance is essential for developing effective skin cancer treatments. Researching these factors enables the creation of combination therapies that overcome resistance, enhancing treatment efficacy. This leads to better outcomes by prolonging remission periods and preventing recurrence, addressing one of the significant challenges in oncology.

5. Economic Burden Reducing the financial burden of skin cancer treatment involves developing cost-effective therapeutic strategies. Economic studies guide the creation of affordable care models, ensuring fair access. Addressing economic disparities allows more patients to benefit from advanced treatment options, promoting overall healthcare sustainability and improving long-term disease management.

© 2025, IJCSMC All Rights Reserved, ZAIN Publications, Fridhemsgatan 62, 112 46, Stockholm, Sweden

6. Patient Perspectives Integrating patient perspectives ensures new technologies align with patient needs and preferences. Research into attitudes toward AI and novel diagnostic tools enhances acceptance and adherence. Involving patients in design and implementation fosters trust and collaboration, resulting in more effective, user-centered treatments responsive to real-world concerns and experiences.

7. Machine Learning and AI Machine learning (ML) and AI play pivotal roles in diagnosing and treating skin cancer by analyzing large datasets and detecting patterns unseen by the human eye. Validating these technologies in clinical settings ensures reliability and addresses ethical considerations. AI-driven approaches increase diagnostic accuracy, streamline workflows, and provide personalized treatment plans tailored to individual patient profiles.

8. Molecular Biology advances skin cancer treatment by identifying genetic markers and understanding cancer progression. Personalized therapies are developed by studying molecular mechanisms, allowing targeted interventions that address specific cancer subtypes. Through innovative, research-backed therapeutic strategies, this leads to more effective treatments, reduced resistance, and improved survival rates.

VI. DISCUSSION

The study to address research gaps in the diagnosis and treatment of skin cancer involves a multifaceted approach. This also requires collaboration between technology developers, healthcare providers and policymakers to develop affordable, accessible and user-friendly diagnostic tools. Rigorous clinical studies must validate these technologies and ensure seamless integration into clinical workflows. Early detection of skin cancer, particularly nonmelanoma types, is another critical area that needs to be improved. Developing non-invasive, cost-effective, and widely accessible early detection techniques is crucial. This includes research into new biomarkers, imaging technologies, and AI algorithms that can accurately detect early-stage skin cancer [38][7].

Public awareness campaigns and education programs are crucial to promote regular skin examinations and early consultations with healthcare professionals. However, challenges such as ensuring targeted delivery, long-term safety, and regulatory hurdles must be addressed. Interdisciplinary collaboration between researchers, clinicians, and regulators is necessary to develop safe, effective, and affordable nanotechnology-based treatments for skin cancer. Drug resistance to the treatment of skin cancer represents a significant challenge, especially in advanced stages. To improve treatment outcomes, it is important to understand the mechanisms of drug resistance and develop strategies to overcome them. Research is needed to identify genetic and molecular factors contributing to drug resistance and develop combination therapies. The economic burden of treating skin cancer highlights the need for cost-effective strategies. It is necessary to research the use of generic drugs, develop more cost-effective diagnostic tools, and implement preventive measures to reduce the incidence of skin cancer. Health economic studies are needed to assess the cost-effectiveness of new treatments and technologies [48].

Incorporating the patient perspective into developing and implementing new technologies for early detection and treatment is critical. To ensure that these technologies meet patient needs and preferences, research into patient attitudes toward AI and other advanced technologies is required [54]. Patient-centered approaches should be designed and implemented to promote trust and collaboration. Finally, validation of machine learning and AI technologies in clinical settings is critical. This includes validating AI algorithms against large, diverse data sets and conducting clinical trials to evaluate their performance [55]. Considering ethical and legal implications such as privacy, algorithmic bias, and accountability ensures that AI treatments for skin cancer are safe, effective, and ethical. By adhering to this, we can close the research gaps in diagnosing and treating skin cancer, ultimately improving patient outcomes and reducing the disease's impact on global health.

VII. CONCLUSION

Ultimately, closing the research gaps in diagnosing and treating skin cancer requires a comprehensive and multifaceted approach. Integrating advanced diagnostic technologies, such as electrical impedance spectroscopy (EIS) and multispectral imaging, into clinical practice is critical to improving early detection and accuracy. The development of non-invasive, cost-effective, and widely accessible screening techniques, as well as public awareness campaigns, can significantly reduce the morbidity and mortality associated with skin cancer. Nanotechnology offers promising potential for the targeted delivery of therapeutic agents, but safety, efficacy, and regulatory hurdles must be addressed. Understanding and overcoming drug resistance is critical to improving treatment outcomes, and research into genetic and molecular factors is needed. Reducing the economic burden of skin cancer treatment through cost-effective strategies and health economic studies is critical to ensuring equitable access to health care. Incorporating the patient perspective into developing new technologies and validating machine learning and AI technologies in clinical settings are critical to developing compelling and acceptable solutions. By following this methodology, we can improve the diagnosis, treatment,

© 2025, IJCSMC All Rights Reserved, ZAIN Publications, Fridhemsgatan 62, 112 46, Stockholm, Sweden

and overall management of skin cancer, ultimately leading to better outcomes for patients and reducing the impact of the disease on global health.

REFERENCES

[1]. U. D. H. S. US Department; Human Services, "Skin Cancer as a Major Public Health Problem." Feb. 01, 2023. Accessed: Jan. 10, 2025. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK247164/

[2]. R. J. Hay et al., "The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions," Oct. 28, 2013, Elsevier BV. doi: 10.1038/jid.2013.446.

[3]. M. F. Simões, J. Sousa, and A. A. C. C. Pais, "Skin cancer and new treatment perspectives: A review," Cancer Letters, vol. 357, no. 1. Elsevier BV, p. 8, Nov. 11, 2014. doi: 10.1016/j.canlet.2014.11.001.

[4]. H. A. Owida, "Developments and Clinical Applications of Noninvasive Optical Technologies for Skin Cancer Diagnosis," Journal of Skin Cancer, vol. 2022. Hindawi Publishing Corporation, p. 1, Nov. 18, 2022. doi: 10.1155/2022/9218847.

[5]. J. K. Cullen, J. L. Simmons, P. G. Parsons, and G. M. Boyle, "Topical treatments for skin cancer," Advanced Drug Delivery Reviews, vol. 153. Elsevier BV, p. 54, Nov. 06, 2019. doi: 10.1016/j.addr.2019.11.002.

[6]. K. Todorova and A. Mandinova, "Novel approaches for managing aged skin and nonmelanoma skin cancer," Advanced Drug Delivery Reviews, vol. 153. Elsevier BV, p. 18, Jan. 01, 2020. doi: 10.1016/j.addr.2020.06.004.

[7]. E. L. Psaty and A. C. Halpern, "Current and emerging technologies in melanoma diagnosis: the state of the art," Clinics in Dermatology, vol. 27, no. 1. Elsevier BV, p. 35, Dec. 17, 2008. doi: 10.1016/j.clindermatol.2008.09.004.

[8]. J. Malvehy et al., "Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety," May 19, 2014, Oxford University Press. doi: 10.1111/bjd.13121.

[9]. J. M. Jung, J. Y. Cho, W. J. Lee, S. E. Chang, M. W. Lee, and C. H. Won, "Emerging Minimally Invasive Technologies for the Detection of Skin Cancer," Journal of Personalized Medicine, vol. 11, no. 10. Multidisciplinary Digital Publishing Institute, p. 951, Sep. 24, 2021. doi: 10.3390/jpm11100951.

[10]. S. J. Divito and L. K. Ferris, "Advances and short comings in the early diagnosis of melanoma," Melanoma Research, vol. 20, no. 6. Lippincott Williams & Wilkins, p. 450, Sep. 21, 2010. doi: 10.1097/cmr.0b013e32833faf7e.

[11]. Gery P Guy, CDC, Atlanta, Georgia, Donatus U Ekwueme, CDC, Atlanta, Georgia, Florence K Tangka, CDC, Atlanta, Georgia, Lisa C Richardson, CDC, Atlanta, Georgia, "Melanoma treatment costs: a systematic review of the literature, 1990-2011." Nov. 2023. Accessed: Jan. 10, 2025. [Online]. Available: https://ajpm-online.net/retrieve/pii/S0749379712005363

[12]. N. Codella et al., "Skin Lesion Analysis Toward Melanoma Detection 2018: A Challenge Hosted by the International Skin Imaging Collaboration (ISIC)," Jan. 01, 2019, Cornell University. doi: 10.48550/arxiv.1902.03368.

[13]. L. J. Loescher, M. Janda, H. P. Soyer, K. Shea, and C. Curiel-Lewandrowski, "Advances in Skin Cancer Early Detection and Diagnosis," Aug. 01, 2013, Elsevier BV. doi: 10.1016/j.soncn.2013.06.003.

[14]. R. Tow et al., "Recent Advances in Clinical Research for Skin Cancer Chemoprevention," Cancers, vol. 15, no. 15. Multidisciplinary Digital Publishing Institute, p. 3819, Jul. 27, 2023. doi: 10.3390/cancers15153819.

[15]. C. Zhang, X. Zhu, S. Hou, W. Pan, and W. Liao, "Functionalization of Nanomaterials for Skin Cancer Theranostics," Frontiers in Bioengineering and Biotechnology, vol. 10. Frontiers Media, Apr. 26, 2022. doi: 10.3389/fbioe.2022.887548.

[16]. D. M. Beswick, A. Kaushik, and D. Beinart, "Biomedical device innovation methodology: applications in biophotonics," Dec. 14, 2017, SPIE. doi: 10.1117/1.jbo.23.2.021102.

[17]. D. Yogev, T. Goldberg, A. Arami, S. Tejman-Yarden, T. E. Winkler, and B. M. Maoz, "Current state of the art and future directions for implantable sensors in medical technology: Clinical needs and engineering challenges," APL Bioengineering, vol. 7, no. 3. AIP Publishing, Sep. 01, 2023. doi: 10.1063/5.0152290.

[18]. L. A. DeLouise, "Applications of Nanotechnology in Dermatology," Journal of Investigative Dermatology, vol. 132, no. 3. Elsevier BV, p. 964, Jan. 06, 2012. doi: 10.1038/jid.2011.425.

[19]. P. Morganti, "Use and potential of nanotechnology in cosmetic dermatology," Feb. 01, 2010, Dove Medical Press. doi: 10.2147/ccid.s4506.

[20]. C. Kelly, A. Karthikesalingam, M. Suleyman, G. S. Corrado, and D. King, "Key challenges for delivering clinical impact with artificial intelligence," Oct. 29, 2019, BioMed Central. doi: 10.1186/s12916-019-1426-2.

[21]. E. Q. Wu, K. Wu, R. Daneshjou, D. Ouyang, D. E. Ho, and J. Zou, "How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals," Apr. 01, 2021, Nature Portfolio. doi: 10.1038/s41591-021-01312-x.

[22]. K. Das et al., "Machine Learning and Its Application in Skin Cancer," International Journal of Environmental Research and Public Health, vol. 18, no. 24. Multidisciplinary Digital Publishing Institute, p. 13409, Dec. 20, 2021. doi: 10.3390/ijerph182413409.

[23]. D.-H. Gam, J. Park, J. Kim, D.-H. Beak, and J. Kim, "Effects of Allium sativum Stem Extract on Growth and Migration in Melanoma Cells through Inhibition of VEGF, MMP-2, and MMP-9 Genes Expression," Dec. 21, 2021, Multidisciplinary Digital Publishing Institute. doi: 10.3390/molecules27010021.

[24]. C. Dianzani et al., "Drug Delivery Nanoparticles in Skin Cancers," BioMed Research International, vol. 2014. Hindawi Publishing Corporation, p. 1, Jan. 01, 2014. doi: 10.1155/2014/895986.

© 2025, IJCSMC All Rights Reserved, ZAIN Publications, Fridhemsgatan 62, 112 46, Stockholm, Sweden

[25]. S. Anil, P. Porwal, and A. Porwal, "Transforming Dental Caries Diagnosis Through Artificial Intelligence-Based Techniques," Cureus. Cureus, Inc., Jul. 11, 2023. doi: 10.7759/cureus.41694.

[26]. N. Junaid et al., "Development, Application, and Performance of Artificial Intelligence in Cephalometric Landmark Identification and Diagnosis: A Systematic Review," Healthcare, vol. 10, no. 12. Multidisciplinary Digital Publishing Institute, p. 2454, Dec. 05, 2022. doi: 10.3390/healthcare10122454.

[27]. F. Mayta–Tovalino, A. Munive-Degregori, S. Luza, F. C. Cárdenas-Mariño, M. E. Guerrero, and J. Barja–Ore, "Applications and perspectives of artificial intelligence, machine learning and 'dentronics' in dentistry: A literature review," Journal of International Society of Preventive and Community Dentistry, vol. 13, no. 1. Medknow, p. 1, Jan. 01, 2023. doi: 10.4103/jispcd.jispcd_35_22.

[28]. J. Lee, D. Kim, S. Jeong, and S. Choi, "Detection and diagnosis of dental caries using a deep learning-based convolutional neural network algorithm," Jul. 26, 2018, Elsevier BV. doi: 10.1016/j.jdent.2018.07.015.

[29]. S. Q. Wang, H. Rabinovitz, A. W. Kopf, and M. Oliviero, "Current technologies for the in vivo diagnosis of cutaneous melanomas," Clinics in Dermatology, vol. 22, no. 3. Elsevier BV, p. 217, May 01, 2004. doi: 10.1016/j.clindermatol.2003.12.008.

[30]. H. T. Hensin Tsao et all Jeannette M. Olazagasti, Kelly M. Cordoro, Jerry D. Brewer, Susan C. Taylor, Jeremy S. Bordeaux, Mary-Margaret Chren, Arthur J. Sober, Connie Tegeler, Reva Bhushan, Wendy Smith Begolka, "Early detection of melanoma: reviewing the ABCDEs." Nov. 01, 2023. Accessed: Jan. 10, 2025. [Online]. Available: https://jaad.org/retrieve/pii/S0190962215000900

[31]. J. N. Cormier, R. K. Voss, T. Woods, K. D. Cromwell, and K. C. Nelson, "Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis," Patient Related Outcome Measures. Dove Medical Press, p. 229, Nov. 01, 2015. doi: 10.2147/prom.s69351.

[32]. R. Marks, "Epidemiology of melanoma," Clinical and Experimental Dermatology, vol. 25, no. 6. Oxford University Press, p. 459, Nov. 01, 2000. doi: 10.1046/j.1365-2230.2000.00693.x.

[33]. P. Nagarajan et al., "Keratinocyte Carcinomas: Current Concepts and Future Research Priorities," Clinical Cancer Research, vol. 25, no. 8. American Association for Cancer Research, p. 2379, Jan. 25, 2019. doi: 10.1158/1078-0432.ccr-18-1122.

[34]. I. Falcone et al., "Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy," Cancers, vol. 12, no. 10. Multidisciplinary Digital Publishing Institute, p. 2870, Oct. 06, 2020. doi: 10.3390/cancers12102870.

[35]. V. S. LeBleu, "Imaging the Tumor Microenvironment," The Cancer Journal, vol. 21, no. 3. Lippincott Williams & Wilkins, p. 174, May 01, 2015. doi: 10.1097/ppo.0000000000000118.

[36]. K.-M. Kuo, P. C. Talley, and C.-S. Chang, "The accuracy of artificial intelligence used for nonmelanoma skin cancer diagnoses: a meta-analysis," BMC Medical Informatics and Decision Making, vol. 23, no. 1. BioMed Central, Jul. 28, 2023. doi: 10.1186/s12911-023-02229-w.

[37]. A. Marka, J. B. Carter, E. Toto, and S. Hassanpour, "Automated detection of nonmelanoma skin cancer using digital images: a systematic review," BMC Medical Imaging, vol. 19, no. 1. BioMed Central, Feb. 28, 2019. doi: 10.1186/s12880-019-0307-7.

[38]. H. Stafford et al., "Nonmelanoma Skin Cancer Detection in the Age of Advanced Technology: A Review," Cancers, vol. 15, no. 12. Multidisciplinary Digital Publishing Institute, p. 3094, Jun. 07, 2023. doi: 10.3390/cancers15123094.

[39]. J. J. Luke and P. A. Ott, "New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy," Drug Healthcare and Patient Safety. Dove Medical Press, p. 77, Jun. 01, 2014. doi: 10.2147/dhps.s39568.

[40]. C. Lee, C. M. Thomas, and K. Ng, "An Overview of the Changing Landscape of Treatment for Advanced Melanoma," Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, vol. 37, no. 3. Wiley, p. 319, Jan. 04, 2017. doi: 10.1002/phar.1895.

[41]. S. A. Boppart and R. Richards-Kortum, "Point-of-care and point-of-procedure optical imaging technologies for primary care and global health," Science Translational Medicine, vol. 6, no. 253. American Association for the Advancement of Science, Sep. 10, 2014. doi: 10.1126/scitranslmed.3009725.

[42]. K. Haney, P. Tandon, R. L. Divi, M. Ossandon, H. Baker, and P. C. Pearlman, "The Role of Affordable, Point-of-Care Technologies for Cancer Care in Low- and Middle-Income Countries: A Review and Commentary," IEEE Journal of Translational Engineering in Health and Medicine, vol. 5. Institute of Electrical and Electronics Engineers, p. 1, Jan. 01, 2017. doi: 10.1109/jtehm.2017.2761764.

[43]. R. El-Kareh, O. Hasan, and G. D. Schiff, "Use of health information technology to reduce diagnostic errors," BMJ Quality & Safety, vol. 22. BMJ, Jul. 13, 2013. doi: 10.1136/bmjqs-2013-001884.

[44]. A. G. C. Pacheco and R. A. Krohling, "Recent advances in deep learning applied to skin cancer detection," Jan. 01, 2019, Cornell University. doi: 10.48550/arxiv.1912.03280.

[45]. V. Terushkin and A. C. Halpern, "Melanoma Early Detection," Hematology/Oncology Clinics of North America, vol. 23, no. 3. Elsevier BV, p. 481, May 22, 2009. doi: 10.1016/j.hoc.2009.03.001.

[46]. S. Dehkharghani, J. Bible, J. G. Chen, S. R. Feldman, and A. B. Fleischer, "The economic burden of skin disease in the United States," Mar. 27, 2003, Elsevier BV. doi: 10.1067/mjd.2003.178.

[47]. L. G. Gordon and D. Rowell, "Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening," European Journal of Cancer Prevention, vol. 24, no. 2. Lippincott Williams & Wilkins, p. 141, Aug. 12, 2014. doi: 10.1097/cej.0000000000000056.

[48]. C. A. Nelson et al., "Patient Perspectives on the Use of Artificial Intelligence for Skin Cancer Screening," Mar. 11, 2020, American Medical Association. doi: 10.1001/jamadermatol.2019.5014.

[49]. A. M. S. Gregoor et al., "An artificial intelligence based app for skin cancer detection evaluated in a population based setting," May 20, 2023, Nature Portfolio. doi: 10.1038/s41746-023-00831-w.

© 2025, IJCSMC All Rights Reserved, ZAIN Publications, Fridhemsgatan 62, 112 46, Stockholm, Sweden

[50]. Carrie L Kovarik, "Patient Perspectives on the Use of Artificial Intelligence." Feb. 2023. Accessed: Jan. 10, 2025. [Online]. Available: https://jamanetwork.com/journals/jamadermatology/article-abstract/2762708

[51]. A. Kawsar, K. Hussain, D. Kalsi, P. Kemos, H. Marsden, and L. Thomas, "Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway," Nov. 16, 2023, Frontiers Media. doi: 10.3389/fmed.2023.1259595.

[52]. M. Dildar et al., "Skin Cancer Detection: A Review Using Deep Learning Techniques," International Journal of Environmental Research and Public Health, vol. 18, no. 10. Multidisciplinary Digital Publishing Institute, p. 5479, May 20, 2021. doi: 10.3390/ijerph18105479.

[53]. M. S. Goyal, T. Knackstedt, S. Yan, and S. Hassanpour, "Artificial Intelligence-Based Image Classification for Diagnosis of Skin Cancer: Challenges and Opportunities," Jan. 01, 2019, Cornell University. doi: 10.48550/arxiv.1911.11872.

[54]. J. Richardson et al., "A framework for examining patient attitudes regarding applications of artificial intelligence in healthcare," Jan. 01, 2022, SAGE Publishing. doi: 10.1177/20552076221089084.

[55]. K. C. J. K. A. S. M. C. G. K. D. Kelly; Christopher et al, "Key challenges for delivering clinical impact with artificial intelligence - BMC Medicine." Feb. 01, 2023. Accessed: Jan. 10, 2025. [Online]. Available: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1426-2

© 2025, IJCSMC All Rights Reserved, ZAIN Publications, Fridhemsgatan 62, 112 46, Stockholm, Sweden